Nektar Therapeutics
NKTR· Nasdaq
Released Aug 13, 2026, after the close
10-Q filed Aug 14, 2026, 45 days after period end · 0001193125-26-349805
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $10.13M | $11.18M | $23.49M | $20.50M |
| Net Income | -$40.62M | -$41.59M | -$52.36M | -$51.12M |
| EPS Diluted |
Nektar Therapeutics · CIK 906709 · Engraved from SEC EDGAR
| -$1.23 |
| -$2.95 |
| -$3.76 |
| -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.